Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
Antony D. Loebel, MD
JCP
Original Research
Long-Term Safety and Efficacy of Ziprasidone in Subpopulations of Patients With Bipolar Mania
June 17, 2009
Marcio Versiani
,
Lewis Warrington
,
Antony D. Loebel
, et al
JCP
Original Research
Ziprasidone in Treatment-Resistant Schizophrenia: A 52-Week, Open-Label Continuation Study
September 17, 2007
Antony D. Loebel
,
Sumant Khanna
,
Sunita Rajadhyaksha
, et al
PCC
Original Research
Change in Framingham Risk Score in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, 6-Week Trial of Ziprasidone and Olanzapine
December 15, 2006
Megan C. del Valle
,
Antony D. Loebel
,
Stephen Murray Ruoyong
, et al
JCP
Letter to the Editor
Dr. Addington and Colleagues reply to Methodological Issues in a Comparative Study of Ziprasidone and Risperidone Methodological Issues in a Comparative Study of Ziprasidone and Risperidone
January 16, 2006
Donald E. N. Addington
,
Christos Pantelis
,
Antony D. Loebel
, et al
